Vericel (VCEL) Competitors $32.44 +0.92 (+2.92%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$33.32 +0.88 (+2.70%) As of 10/3/2025 05:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VCEL vs. CYTK, NUVL, AXSM, TGTX, CRSP, MTSR, MRUS, KRYS, PTCT, and MENSShould you be buying Vericel stock or one of its competitors? The main competitors of Vericel include Cytokinetics (CYTK), Nuvalent (NUVL), Axsome Therapeutics (AXSM), TG Therapeutics (TGTX), CRISPR Therapeutics (CRSP), Metsera (MTSR), Merus (MRUS), Krystal Biotech (KRYS), PTC Therapeutics (PTCT), and Jyong Biotech (MENS). These companies are all part of the "pharmaceutical products" industry. Vericel vs. Its Competitors Cytokinetics Nuvalent Axsome Therapeutics TG Therapeutics CRISPR Therapeutics Metsera Merus Krystal Biotech PTC Therapeutics Jyong Biotech Vericel (NASDAQ:VCEL) and Cytokinetics (NASDAQ:CYTK) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings and risk. Which has stronger earnings & valuation, VCEL or CYTK? Vericel has higher revenue and earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVericel$237.22M6.90$10.36M$0.12270.33Cytokinetics$18.47M369.09-$589.53M-$5.10-11.17 Does the media refer more to VCEL or CYTK? In the previous week, Cytokinetics had 44 more articles in the media than Vericel. MarketBeat recorded 45 mentions for Cytokinetics and 1 mentions for Vericel. Vericel's average media sentiment score of 1.76 beat Cytokinetics' score of 0.20 indicating that Vericel is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vericel 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Cytokinetics 6 Very Positive mention(s) 2 Positive mention(s) 31 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Is VCEL or CYTK more profitable? Vericel has a net margin of 2.85% compared to Cytokinetics' net margin of -707.17%. Vericel's return on equity of 2.47% beat Cytokinetics' return on equity.Company Net Margins Return on Equity Return on Assets Vericel2.85% 2.47% 1.69% Cytokinetics -707.17%N/A -45.52% Do analysts rate VCEL or CYTK? Vericel presently has a consensus target price of $60.40, indicating a potential upside of 86.19%. Cytokinetics has a consensus target price of $75.86, indicating a potential upside of 33.15%. Given Vericel's higher possible upside, equities research analysts plainly believe Vericel is more favorable than Cytokinetics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vericel 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50Cytokinetics 1 Sell rating(s) 3 Hold rating(s) 12 Buy rating(s) 1 Strong Buy rating(s) 2.76 Which has more risk & volatility, VCEL or CYTK? Vericel has a beta of 1.39, suggesting that its share price is 39% more volatile than the S&P 500. Comparatively, Cytokinetics has a beta of 0.67, suggesting that its share price is 33% less volatile than the S&P 500. SummaryVericel beats Cytokinetics on 10 of the 15 factors compared between the two stocks. Get Vericel News Delivered to You Automatically Sign up to receive the latest news and ratings for VCEL and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VCEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VCEL vs. The Competition Export to ExcelMetricVericelMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.64B$3.36B$6.13B$10.58BDividend YieldN/A2.28%5.65%4.69%P/E Ratio270.3622.2886.9626.71Price / Sales6.90458.33605.32131.77Price / Cash103.8147.8637.9061.31Price / Book5.489.9312.556.55Net Income$10.36M-$52.80M$3.31B$277.50M7 Day Performance7.31%5.22%4.28%2.42%1 Month Performance-4.73%10.61%6.90%8.63%1 Year Performance-25.18%25.03%70.54%31.60% Vericel Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VCELVericel3.1551 of 5 stars$32.44+2.9%$60.40+86.2%-25.2%$1.64B$237.22M270.36300Positive NewsCYTKCytokinetics3.8736 of 5 stars$53.89+6.9%$75.71+40.5%+0.5%$6.03B$18.47M-10.57250Trending NewsAnalyst ForecastInsider TradeNUVLNuvalent3.2701 of 5 stars$84.84+4.2%$119.50+40.9%-19.7%$5.87BN/A-17.3140Insider TradeAXSMAxsome Therapeutics4.8368 of 5 stars$117.62+0.7%$177.86+51.2%+38.9%$5.83B$385.69M-23.20380Trending NewsAnalyst ForecastAnalyst RevisionTGTXTG Therapeutics4.3888 of 5 stars$36.83+3.7%$48.00+30.3%+65.1%$5.63B$329M99.54290CRSPCRISPR Therapeutics1.9274 of 5 stars$63.77+3.4%$71.50+12.1%+49.3%$5.61B$37.31M-11.74460News CoverageMTSRMetseraN/A$52.10-0.3%$58.50+12.3%N/A$5.49BN/A0.0081Analyst DowngradeGap UpMRUSMerus1.1222 of 5 stars$93.67+36.0%$92.73-1.0%+82.1%$5.21B$36.13M-17.0337Trending NewsAnalyst DowngradeOptions VolumeAnalyst RevisionHigh Trading VolumeKRYSKrystal Biotech4.6773 of 5 stars$176.75+5.3%$209.00+18.2%+3.5%$4.86B$290.52M35.92210Positive NewsPTCTPTC Therapeutics3.4226 of 5 stars$60.65+2.8%$69.00+13.8%+86.2%$4.69B$806.78M8.701,410MENSJyong BiotechN/A$50.00-16.3%N/AN/A$4.54BN/A0.0031 Related Companies and Tools Related Companies CYTK Competitors NUVL Competitors AXSM Competitors TGTX Competitors CRSP Competitors MTSR Competitors MRUS Competitors KRYS Competitors PTCT Competitors MENS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VCEL) was last updated on 10/5/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredMelt-up warning Porter Stansberry says this bull market is past the “safe zone” and racing toward an event horizon — and in hi...Porter & Company | SponsoredThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top ad...Weiss Ratings | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vericel Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Vericel With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
